Recombinant FVII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy and inhibitor development after seven study years

被引：0
|
作者：
Lusher, J
Arkin, S
Abildgaard, CF
Hurst, A
机构：
[1] MT SINAI SCH MED, NEW YORK, NY USA
[2] WAYNE STATE UNIV, DETROIT, MI USA
[3] UNIV CALIF DAVIS, SACRAMENTO, CA 95817 USA
[4] BAYER CORP, BERKELEY, CA USA
来源：
THROMBOSIS AND HAEMOSTASIS | 1997年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：PD664 / PD664
页数：1
相关论文
共 50 条
  • [21] A safety and efficacy evaluation of rFIX in previously untreated patients (PUPS) with severe and moderately severe hemophilia B
    Shapiro, A
    Pasi, KJ
    Courter, S
    Tubridy, K
    THROMBOSIS AND HAEMOSTASIS, 1997, : PS212 - PS212
  • [22] Risk of bleeding and inhibitor development after circumcision of Previously Untreated (PUPs) or Minimally Treated (MTPs) severe hemophilia A patients
    Elalfy, M.
    Elbarbary, N.
    Eldebeiky, M.
    El Danasoury, A.
    HAEMOPHILIA, 2012, 18 : 89 - 89
  • [23] Safety, efficacy and inhibitor development in previously untreated patients (PUPs) treated exclusively with recombinant B-domain deleted F VIII (rVIII-SQ): 2.5 study years.
    Lusher, JM
    Spira, J
    BLOOD, 1997, 90 (10) : 2664 - 2664
  • [24] INHIBITOR DEVELOPMENT IN PREVIOUSLY UNTREATMENT PATIENTS (PUPS) WITH HEMOPHILIA RECEIVING KOGENATE - 4.5 YEAR FOLLOW-UP DATA, INCLUDING RESPONSE TO IMMUNE TOLERANCE (IT) WITH KOGENATE
    LUSHER, JM
    ARKIN, S
    ABILDGAARD, CF
    INWOOD, M
    ZIMMERMANN, R
    HILGARTNER, M
    HURST, D
    BLOOD, 1993, 82 (10) : A153 - A153
  • [25] Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B
    Nolan, Beatrice
    Klukowska, Anna
    Shapiro, Amy
    Rauch, Antoine
    Recht, Michael
    Ragni, Margaret
    Curtin, Julie
    Gunawardena, Sriya
    Mukhopadhyay, Sutirtha
    Jayawardene, Deepthi
    Winding, Bent
    Fischer, Kathelijn
    Liesner, Raina
    BLOOD ADVANCES, 2021, 5 (13) : 2732 - 2739
  • [26] Recombinant factor IX (rFIX) in the treatment of previously untreated patients (PUPS) with severe or moderately severe hemophilia B
    Shapiro, A
    Abshire, T
    Gill, J
    Kisker, T
    Pasi, J
    Rodriguez, D
    Courter, S
    BLOOD, 1998, 92 (10) : 356A - 356A
  • [27] Safety and efficacy in previously untreated patients (PUPs) treated with recombinant B-domain deleted recombinant FVIII (BDDrFVIII).
    Philipp, CS
    Shapiro, AD
    Gruppo, RA
    Bedrosian, CL
    Nissen, S
    Nguyen, K
    BLOOD, 2001, 98 (11) : 39A - 40A
  • [28] Safety and immunogenicity of recombinant factor VIII (Recombinate(TM)) in previously untreated patients (PUPs): A 6.5 year update
    Gruppo, R
    Bray, GL
    Schroth, P
    Perry, M
    Gomperts, ED
    THROMBOSIS AND HAEMOSTASIS, 1997, : PD663 - PD663
  • [29] DETERMINING INHIBITOR-DEVELOPMENT RISK IN PREVIOUSLY UNTREATED HEMOPHILIA-A PATIENTS TREATED (PUPS) WITH RECOMBINANT FACTOR-VIII (RECOMBINATE(TM))
    LEE, ML
    COURTER, S
    GOMPERTS, E
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 856 - 856
  • [30] Inhibitor development in previously untreated patients (PUPs) with hemophilia A and B: A prospective 23-year-follow-up
    Ettingshausen, CE
    Zyschka, A
    Oldenburg, J
    Saguer, IM
    Ehrenforth, S
    Kreuz, W
    Goethe, JW
    THROMBOSIS AND HAEMOSTASIS, 1999, : 410 - 410
12345